Diabetes

BRONX, N.Y. — A new study conducted by researchers at Yeshiva University's Albert Einstein College of Medicine found that high blood-sugar levels may be associated with an increased risk of colorectal cancer.

Researchers examined the fasting blood sugar and insulin levels of nearly 5,000 postmenopausal women — all of whom were enrolled in the National Institutes of Health's landmark Women's Health Initiative study — several times over a 12-year period.

INDIANAPOLIS — Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

Drug maker Eli Lilly is partnering with Brigham and Women's Hospital in Boston in a study that started in July and has enrolled 4,500 people in 17 countries to find out why many people with the disease resist a progression of insulin therapy.

SILVER SPRING, Md. — In an effort to help advance the development of devices that automatically monitor blood glucose and provide proper insulin doses in people with Type 1 diabetes, the Food and Drug Administration has issued draft guidance to help investigators and manufacturers as they develop and seek approval for these products.

NEW YORK — Record-breaking attendance, a high-profile keynote speaker, four engaging panel discussions on some of the hottest issues facing the industry and exclusive consumer videos set the stage for the 13th annual Drug Store News Industry Issues Summit held on Tuesday in New York.

ATLANTA — Many elderly patients put themselves at risk for emergency hospitalization due to adverse drug events, according to a new Centers for Disease Control and Prevention study published in the New England Journal of Medicine.

EAST LANSING, Mich. — A drug commonly used to treat Type 2 diabetes may reduce the risk of diabetes-associated cancers, including breast cancer, according to a new study.

OSAKA, Japan — A U.S. subsidiary of Takeda Pharmaceutical has filed for regulatory approval of a drug designed to treat Type 2 diabetes, the company said.

The Takeda Global Research and Development Center filed with the Food and Drug Administration for approval of an alogliptin-metformin combination tablet. The company expects the FDA to review the application within the next 10 months.

WAUKESHA, Wis. — Hamacher Resource Group will be participating in The Drug Store News Group's Diabetes Leadership Forum, part of the Industry Issues conference, to be held Nov. 29 at the New York Athletic Club. HRG VP Dave Wendland will moderate the discussion for the eighth year in a row. The panel will include six of the leading health and beauty retailers in the country.